Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
Guilhot F, Abgrall JF, Harousseau JL, Bauters F, Brice P, Dine G, Tilly H, Ifrah N, Cassasus P, Rochant H, et al. Guilhot F, et al. Among authors: ifrah n. Leuk Lymphoma. 1993;11 Suppl 1:181-3. doi: 10.3109/10428199309047883. Leuk Lymphoma. 1993. PMID: 8251893 Clinical Trial.
A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.
Guilhot F, Lamagnère JP, Harousseau JL, Tilly H, Casassus P, Ifrah N, Rochant H, Bauters F, Dine G, Tanzer J. Guilhot F, et al. Among authors: ifrah n. Eur J Cancer. 1991;27 Suppl 4:S26. doi: 10.1016/0277-5379(91)90561-q. Eur J Cancer. 1991. PMID: 1799470 Clinical Trial. No abstract available.
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.
Guilhot F, Guerci A, Fiere D, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Rochant H, Najman A, Nicolini F, Colombat P, Abgrall JF, Ifrah N, Brière J, Bauters F, Navarro M, Morice P, Bordessoule D, Vilque JP, Desablens B, Tertian G, Blanc M, Chastang C, Tanzer J. Guilhot F, et al. Among authors: ifrah n. Bone Marrow Transplant. 1996 May;17 Suppl 3:S29-31. Bone Marrow Transplant. 1996. PMID: 8769697 Clinical Trial. No abstract available.
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J, Tertain G, Blanc M, Bauduer F, Brière J, Abgrall JF, Pegourie-Bandelier B, Solary E, Cambier N, Coso D, Vilque JP, Delain M, Harousseau JL, Rousselot P, Belhadj K, Morice P, Attal J, Chabin M, Chastang C, Guilhot J, Guilhot F; France Intergroupe des Leucémies Myéloïdes Chroniques. Maloisel F, et al. Among authors: ifrah n. Leukemia. 2002 Apr;16(4):573-80. doi: 10.1038/sj.leu.2402433. Leukemia. 2002. PMID: 11960335 Clinical Trial.
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.
Récher C, Béné MC, Lioure B, Pigneux A, Vey N, Delaunay J, Luquet I, Hunault M, Guyotat D, Bouscary D, Fegueux N, Jourdan E, Lissandre S, Escoffre-Barbe M, Bonmati C, Randriamalala E, Guièze R, Ojeda-Uribe M, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Guardiola P; Groupe Ouest-Est d’ étude des Leucé mies Aiguës et autres. Récher C, et al. Among authors: ifrah n. Leukemia. 2014 Feb;28(2):440-3. doi: 10.1038/leu.2013.290. Epub 2013 Oct 9. Leukemia. 2014. PMID: 24166215 No abstract available.
Intensive therapy for high grade multiple myeloma (MM).
Harousseau JL, Milpied N, Jouet JP, Colombat P, Guilhot F, Laporte JP, Ifrah N, Gandhour C, Casassus P. Harousseau JL, et al. Among authors: ifrah n. Bone Marrow Transplant. 1991;7 Suppl 2:28. Bone Marrow Transplant. 1991. PMID: 1878703 No abstract available.
Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
Jourdan E, Maraninchi D, Reiffers J, Gluckman E, Rio B, Jouet JP, Michallet M, Molina L, Archimbaud E, Harousseau JL, Ifrah N, Attal M, Guilhot F, Kuentz M, Guyotat D, Pico JL, Dauriac C, Legros M, Dreyfus F, Bordigoni P, Leblond V, Gratecos N, Varet B, Auzanneau C, Blaise D, et al. Jourdan E, et al. Among authors: ifrah n. Bone Marrow Transplant. 1997 May;19(9):875-81. doi: 10.1038/sj.bmt.1700761. Bone Marrow Transplant. 1997. PMID: 9156260
305 results